{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:33:51Z","timestamp":1787243631784,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103832","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:04:05Z","timestamp":1651097045000},"page":"103832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis"],"prefix":"10.1016","volume":"63","author":[{"given":"Mokshal H.","family":"Porwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3549-3277","authenticated-orcid":false,"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2022.103832_bib0001","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1684\/ejd.2015.2602","article-title":"Onset of psoriasis upon interferon beta treatment in a multiple sclerosis patient","volume":"26","author":"Amschler","year":"2016","journal-title":"Eur J Dermatology"},{"key":"10.1016\/j.msard.2022.103832_bib0002","first-page":"43","article-title":"A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis","author":"Arslan","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.103832_bib0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bjd.12226","article-title":"Alemtuzumab and chronic plaque psoriasis","volume":"169","author":"Aslam","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.msard.2022.103832_bib0004","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.msard.2022.103832_bib0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"10.1016\/j.msard.2022.103832_bib0006","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","article-title":"Association Between Immune-Related Adverse Events During Anti\u2013PD-1 Therapy and Tumor Mutational Burden","volume":"5","author":"Bomze","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.msard.2022.103832_bib0007","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/exd.13548","article-title":"A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis","volume":"27","author":"Br\u00fcck","year":"2018","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.msard.2022.103832_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2022.103832_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103832_bib0010","article-title":"Ocrelizumab-Induced Psoriasiform Dermatitis in a","volume":"24","author":"Darwin","year":"2018","journal-title":"Patient with Multiple Sclerosis"},{"key":"10.1016\/j.msard.2022.103832_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.msard.2019.03.009","article-title":"A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions","volume":"31","author":"Diebold","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.msard.2022.103832_bib0012","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/JID.2015.350","article-title":"Risk of multiple sclerosis in patients with psoriasis: A Danish nationwide cohort study","volume":"136","author":"Egeberg","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.msard.2022.103832_bib0013","unstructured":"Geils HM, Katz JD, Lathi ES, Stribling IC. Psoriasis Flare during Ocrelizumab Therapy for Relapsing Multiple Sclerosis: Report of 2 Cases. Published online May 2019."},{"issue":"4","key":"10.1016\/j.msard.2022.103832_bib0014","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1352458518763094","article-title":"Cytokine signaling in multiple sclerosis: Lost in translation","volume":"24","author":"G\u00f6bel","year":"2018","journal-title":"Mult Scler J"},{"issue":"6","key":"10.1016\/j.msard.2022.103832_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00128071-200708060-00002","article-title":"Sphingosine-1-phosphate signaling and the skin","volume":"8","author":"Herzinger","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.msard.2022.103832_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.563645","article-title":"Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses","volume":"11","author":"Hilger","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2022.103832_bib0017","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1136\/jnnp-2019-ABN-2.161","article-title":"181\u2005Multiple Sclerosis associated with Psoriasis \u2013 is alemtuzumab the drug of choice?","volume":"90","author":"Karthikeayan","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.103832_bib0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2310\/7750.2010.09063","article-title":"Psoriasis and multiple sclerosis: Is there a link?","volume":"14","author":"Kwok","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"issue":"3","key":"10.1016\/j.msard.2022.103832_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10072-009-0184-x","article-title":"Psoriasis during interferon beta treatment for multiple sclerosis","volume":"31","author":"La Mantia","year":"2010","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.msard.2022.103832_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000492891","article-title":"Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature","volume":"10","author":"Lambrianides","year":"2018","journal-title":"Case Rep Neurol"},{"issue":"3","key":"10.1016\/j.msard.2022.103832_bib0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/157015911796557911","article-title":"Multiple Sclerosis: Pathogenesis and Treatment","volume":"9","author":"Loma","year":"2011","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.msard.2022.103832_bib0022","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol neuroinflammation"},{"issue":"12","key":"10.1016\/j.msard.2022.103832_bib0023","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s00415-012-6713-1","article-title":"Psoriasis during natalizumab treatment for multiple sclerosis","volume":"259","author":"Mill\u00e1n-Pascual","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103832_bib0024","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2018.11.020","article-title":"Palmar pustular psoriasis associated with teriflunomide treatment","volume":"27","author":"Negrotto","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103832_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/CON.0000000000000725","article-title":"Multiple sclerosis risk factors and pathogenesis","author":"Nourbakhsh","year":"2019","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"8","key":"10.1016\/j.msard.2022.103832_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life10080138","article-title":"Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.msard.2022.103832_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1523-1747.1998.00232.x","article-title":"Differential expression of activation epitopes of \u03b21 integrins in psoriasis and normal skin","volume":"111","author":"Pe\u00f1as","year":"1998","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.msard.2022.103832_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2022.103832_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2020.1736553","article-title":"A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis","author":"Reszke","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.msard.2022.103832_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jdermsci.2013.03.006","article-title":"Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis","volume":"71","author":"Schaper","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.msard.2022.103832_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/PTT.S186637","article-title":"<p>A narrative review of psoriasis and multiple sclerosis: links and risks<\/p>","volume":"9","author":"Silfvast-Kaiser","year":"2019","journal-title":"Psoriasis Targets Ther"},{"key":"10.1016\/j.msard.2022.103832_bib0032","article-title":"Dimethyl fumarate modulates the Treg\u2013Th17 cell axis in patients with psoriasis","author":"Sulaimani","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.msard.2022.103832_bib0033","first-page":"1","article-title":"Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis","volume":"2014","author":"Toussirot","year":"2014","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.msard.2022.103832_bib0034","author":"Weber","year":"2022","journal-title":"Mechanism of Action of Glatiramer Acetate in Treatment of Multiple Sclerosis"},{"issue":"2","key":"10.1016\/j.msard.2022.103832_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2022.103832_bib0036","article-title":"Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis","author":"Zhang","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:49Z","timestamp":1761901309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":36,"alternative-id":["S2211034822003443"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103832","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103832"}}